Objectives: To evaluate the AusDiagnostics MT CRE EU assay for the detection of carbapenemase and acquired colistin resistance genes in Gram-negative bacteria.
Introduction
Molecular detection of acquired carbapenemase genes represents the gold standard; however, the majority of currently available commercial assays focus on detection of some or all of the 'big five' carbapenemase families (KPC, OXA-48-like, NDM, VIM and IMP). Such assays also differ in their coverage within the carbapenemase families, with detection of OXA-48-like, and particularly IMP, variants a known problem due to sequence diversity of alleles within these families. 1 Due to the increase of infections caused by carbapenemaseproducing organisms, colistin is often considered an antibiotic of last resort. Most colistin resistance in Enterobacteriaceae arises from mutations in chromosomally encoded genes. However, plasmid-mediated resistance to colistin conferred by mcr gene variants has been described worldwide. mcr genes have also been reported in carbapenemase-producing Enterobacteriaceae (CPE), with mcr-1 reported to be co-located with NDM-5 on the same plasmid in an Escherichia coli isolate from China. 2 In addition to the KPC, OXA-48-like, NDM, VIM and IMP carbapenemases that predominate amongst isolates submitted to PHE's Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit for investigation of carbapenem resistance, rarer carbapenemases of the GES, IMI, SME, FRI, DIM and SPM families have been detected in isolates referred by UK laboratories. [3] [4] [5] [6] The mcr-1 gene has also been detected in some colistinresistant CPE (AMRHAI, unpublished data). These observations highlight the importance of a comprehensive molecular assay for rapid detection or confirmation of carbapenemase and colistin resistance genes by reference laboratories in order to identify infected and colonized patients.
We evaluated the AusDiagnostics MT CRE EU assay (AusDiagnostics, Chesham, UK) for the detection of carbapenemase genes and the transferable colistin resistance determinants mcr-1/-2 in a range of bacterial species. This 16-plex tandem PCR assay allows detection of bla KPC , bla OXA-48-like , bla NDM , bla VIM , bla IMP , bla SIM , bla GIM , bla SPM , bla FRI , bla IMI , bla GES (differentiating ESBL and carbapenemase variants), bla SME and mcr-1/-2.
Materials and methods

Bacterial isolates
Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. sent to the AMRHAI Reference Unit for investigation of carbapenem or colistin resistance were screened using the AusDiagnostics MT CRE EU assay retrospectively (n " 210) and prospectively (n " 182).
These included isolates with carbapenemase or mcr genes detected by in-house PCR (n " 283) and isolates with carbapenem resistance mediated by combinations of ESBL/AmpC plus porin loss and carbapenemsusceptible isolates (n " 109) ( Table 1 ). Some isolates (n " 29) co-produced two carbapenemases. Isolates represented the diversity of carbapenemase alleles seen in the UK based, for most isolates, on WGS results (AMRHAI, 2014 to mid-2016, unpublished data).
AusDiagnostics MT CRE EU assay
The AusDiagnostics MT CRE EU assay is a two-step, nested multiplex tandem PCR.
The assay was performed on two to three colonies grown overnight on Columbia blood or cystine lactose electrolyte deficient (CLED) agar and suspended in tubes containing a sample buffer. The tubes were then loaded onto the AusDiagnostics MT processor platform for template extraction, first round PCR and nested RT-PCR set-up. A 384-PCR plate containing the whole reaction mix was then loaded onto the AusDiagnostics MT analyser for the nested RT-PCR.
Results were automatically interpreted using the AusDiagnostics MT assay software and compared with in-house PCR results. 5, 7, 8 In the case of discrepant results, both in-house PCR and AusDiagnostics MT CRE EU assay were repeated.
Results
The isolate panel initially included 274 carbapenemase producers, three with ESBL GES variants, 14 OXA-23-or OXA-58-producing Acinetobacter baumannii isolates and 22 mcr-producing isolates. Various combinations of carbapenemase genes, of carbapenemase and mcr-1 genes and of carbapenemase genes and ESBL GES variants were detected in 29 isolates (Table 1) .
The AusDiagnostics MT CRE EU assay required minimal handson time (30 min for the set-up of 24 samples) and yielded results in less than 4 h from bacterial culture. It identified most (239/245, 97.5%) of the 'big five' carbapenemase genes previously identified by in-house PCR or WGS, allowing detection of variants of KPC (n " 48; KPC-2, KPC-3, KPC-4 and KPC-23), OXA-48-like (n " 80; OXA-48, OXA-181, OXA-204, OXA-232, OXA-244, OXA-245 and OXA-484), NDM (n " 61; NDM-1, NDM-3, NDM-4, NDM-5 and NDM-7), VIM (n " 26; VIM-1, VIM-2, VIM-4 and VIM-19) and IMP (n " 24; IMP-1, IMP-4, IMP-6, IMP-7, IMP-8, IMP-10, IMP-13, IMP-14 and IMP-29) in Enterobacteriaceae, Pseudomonas and Acinetobacter isolates.
The AusDiagnostics MT CRE EU assay and the repeat in-house PCR testing failed to confirm the presence of carbapenemase genes in five isolates initially identified as positive for bla OXA-181 (n " 1), bla NDM-4 (n " 1) and bla IMP (IMP-1, n " 2; IMP-29, n " 1), suggesting loss of the plasmids harbouring these genes; therefore, these isolates were considered as true negatives. One bla OXA-48-like was not detected due to the original culture being mixed, with a variation in the content of carbapenemase genes within colonies. However, following repeat testing of both the in-house PCR and the AusDiagnostics MT CRE EU assay a bla OXA-48-like gene was detected in this isolate. The AusDiagnostics MT CRE EU assay did not detect bla OXA-436 , which shared 87% nucleotide sequence identity with bla OXA-48 and bla OXA-181 . 9 Isolates of Pseudomonas aeruginosa, Serratia marcescens, Enterobacter cloacae, Klebsiella variicola and Acinetobacter pittii with bla SPM-1 (n " 1), bla SME (n " 2; bla SME-2 and bla SME-4 ), bla FRI-2 (n " 1), bla IMI (n " 7; bla IMI-1 , bla IMI-2 , bla IMI-4 , bla IMI-8 and bla NMC-A ), bla SIM and bla GIM were all correctly identified by the assay.
The AusDiagnostics MT CRE EU assay also allowed differentiation between ESBL and carbapenemase GES variants, correctly identifying 18 bla GES-5 carbapenemase genes and three GES ESBLs (bla GES-1 , bla GES-7 and bla GES-24 ). One bla GES-5 was not initially detected but was correctly identified on repeat testing.
Eighteen out of 22 mcr genes were detected; however, the four 'failed' isolates were also negative on repeat testing by in-house PCR suggesting instability of the mcr-1 plasmid in these isolates and were thus considered as true negatives.
After exclusion of bla OXA-436 and the nine true negatives (due to gene loss on storage), the AusDiagnostics MT CRE EU assay correctly identified 268/268 carbapenemases, 3 GES ESBLs and 18 mcr-1/-2 producers. The specificity of the assay for the detection of OXA-48-like carbapenemases was assessed by testing 14 A. baumannii isolates harbouring bla OXA-23 or bla . No crossreactivity was observed with these or other oxacillinase genes detected by WGS in these isolates.
During the retrospective and prospective evaluations, 8 and 18 false-positive results were observed, respectively, and were mostly due to signals with low concentration in addition to other markers, which led to suspicion over the results. Most of the false-positive results were obtained during the prospective evaluation and an issue with the calibration of the robot arm was suspected. We also identified a problem with the electrical current affecting the quality of the runs and so we have equipped the AusDiagnostics MT with an uninterruptible power supply. Subsequent repeats of the AusDiagnostics MT CRE EU assay resolved all false-positive results.
The overall sensitivity and specificity of the assay were 95.5% (95% CI 91.8-97.8) and 99.8% (95% CI 99.5-99.9), respectively when taking the results from the first run at face value. After repeat of the in-house PCR and the AusDiagnostics MT CRE EU assay, and exclusion of the 10 true negatives, the overall sensitivity and specificity of the assay increased to 100%.
When applying the same criteria for the isolate panel tested prospectively and taking the results from the first run at face value, the overall sensitivity and specificity of the assay were 98.7% (95% CI 92.9-99.9) and 99.4% (95% CI 99.0-99.6), respectively. All values increased on subsequent retesting to 100%.
Discussion
The detection of rarer carbapenemases of the GES, IMI, SME, FRI, DIM and SPM families by PHE's AMRHAI Reference Unit suggests that these genes are circulating in hospital settings in the UK. [3] [4] [5] 10 Although some were linked to foreign travel (SPM), others such as SME (n " 10), FRI-2 (n " 1) and DIM-1 (n " 3) were isolated from patients hospitalized in the UK with no travel history disclosed.
Currently, no single commercial molecular assay allows the detection of all globally circulating carbapenemase genes, although some allow detection of the 'big five' carbapenemase families from bacterial colonies and/or blood cultures. [11] [12] [13] [14] Recently, a published evaluation showed that Carba5, an immunochromatographic assay, is able to rapidly and simultaneously detect KPC, OXA-48-like, NDM, VIM and IMP carbapenemases. 15 However, despite a sensitivity and specificity of 100% and 99.97%, respectively, Carba5 failed to detect a non-targeted carbapenemase of the IMI 
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(n " Detection of carbapenemase and colistin resistance genes JAC family when in-house PCR and Carba NP correctly identified this gene and the carbapenemase activity, respectively. This illustrates the complexity of detection of carbapenemases, where focusing on the most prevalent 'big five' families might overlook detection of rarer or novel carbapenemases, thereby highlighting the importance of considering the results of molecular screening assays in light of phenotypic susceptibility data. Methods relying on carbapenem hydrolysis can be an option; however, they also show limitations with issues for the detection of some variants of OXA-48-like and GES carbapenemases. [16] [17] [18] [19] [20] The AusDiagnostics MT CRE EU assay detected both carbapenemase and ESBL variants of GES. It was able to detect IMP variants such as IMP-4, IMP-7, IMP-8, IMP-13 and IMP-14 not detected in a previous evaluation of Xpert V R Carba-R. 13 Likewise, it was able to detect mcr-1/-2 genes on their own or in combination with carbapenemase genes, which is important for informing infection control and epidemiology.
The choice of a carbapenemase detection method relies on a balance between needs, costs and local epidemiology. The AusDiagnostics MT CRE EU assay allowed detection of the main carbapenemase gene families identified in the UK in Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. (with the exception of oxacillinases found in this genus) and its coverage also allowed detection of a range of rarer carbapenemase types and concomitant detection of any mcr-1/-2 colistin resistance genes. It thereby offers an increased confidence that negative isolates are unlikely to be carbapenemase producers.
